All In Biotech

Drug Trial Radar · NCT03218995

Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping

An Open-Label Safety, Tolerability, and Pharmacokinetics Study of Eteplirsen in Young Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Last checked: Nov 20, 2026Latest source record: Dec 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

15

Actual

Start

Aug 16, 2017

Primary completion

Mar 10, 2021

Study completion Mar 10, 2021

Sponsor

Lead sponsor
Sarepta Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 6 months, up to 48 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, and PK of once-weekly IV infusions of eteplirsen in approximately 12 male participants, ages 6 months to 48 months (inclusive), who have genotypically confirmed DMD with a deletion mutation amenable to exon 51 skipping.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • EteplirsenDrug

    Infusion for intravenous use.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation From Study DrugTime frame: Baseline up to Week 100
  2. Number of Participants With at Least 1 Potentially Clinically Significant Clinical Safety Laboratory AbnormalityTime frame: Baseline up to Week 100
  3. Number of Participants With at Least 1 Markedly Abnormal Vital SignTime frame: Baseline up to Week 100
  4. Abnormal Changes From Baseline or Worsening of Physical Examination FindingsTime frame: Baseline up to Week 100
  5. Number of Participants With at Least 1 Markedly Abnormal Electrocardiogram (ECG) and Echocardiogram (ECHO)Time frame: Weeks 8, 12, 24, 36, 48, 60, 72, 84, 96

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Universitair ziekenhuis Gent

    Ghent, Belgium

  • Armand-Trousseau Hospital

    Paris, France

  • Site Fondazione Policlinico Universitario Agostino Gemelli

    Roma, Italy

  • UCL Great Ormond Street Institute of Child Health

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.